ASP Isotopes Inc. (NASDAQ:ASPI) shares gained in premarket trading after Quantum Leap Energy, the company's wholly owned subsidiary focused on nuclear fuel cycle technologies, disclosed a memorandum of understanding with a European nuclear technology company to evaluate supply of high assay low enriched uranium (HALEU).
The MOU is explicitly non-binding and calls for the parties to study the technical and economic feasibility of a long-term partnership to supply HALEU - defined in the agreement as uranium enriched in uranium-235 at levels greater than 10%.
Under the terms outlined, the European partner would make uranium feedstocks available to QLE’s planned conversion and enrichment facilities. Quantum Leap Energy would then enrich those feedstocks to HALEU for subsequent delivery to the partner, should the assessment and any future agreements proceed.
The memorandum extends through December 31, 2030 and contains non-binding estimates of HALEU quantities. The document contemplates potential deliveries starting in 2028 and scaling up through 2036, with the timing and volumes linked to the partner’s reactor development schedule and resulting fuel demands.
"Securing reliable HALEU supply is one of the most critical challenges facing the advanced nuclear industry today. This MOU is a meaningful step in QLE’s mission to build enrichment capabilities that serve both U.S. and global markets," said Dr. Ryno Pretorius, Chief Executive Officer of Quantum Leap Energy.
The MOU frames a scope of activities that includes assessing operational requirements, gauging production scalability at planned conversion and enrichment facilities, and estimating associated costs and commercial models. The parties retain the option to terminate the agreement early.
Quantum Leap Energy is identified in the announcement as a wholly owned subsidiary of ASP Isotopes dedicated to developing technologies and processes spanning segments of the fission and fusion nuclear fuel cycle.
Context and implications
The announcement provides a preliminary commercial framework for HALEU supply that, if advanced to binding agreements and executed projects, would create an integrated flow in which a European partner supplies feedstock and QLE performs conversion and enrichment. The timeline presented in the MOU ties potential deliveries to the counterparty’s reactor deployment and fuel needs, and the parties explicitly describe volume estimates as non-binding.
Investors responded in premarket trading, with ASP Isotopes shares rising 4.7%.